【摘要】 目的:对比观察卡维地洛、美托洛尔在慢性心力衰竭(CHF)治疗中的疗效和安全性。方法:对88例慢性心力衰竭病人随机分为A组(卡维地洛治疗组)46例,B组(美托洛尔对照组)42例。两组患者基础临床特征相似,应用彩色超声心动图测量患者治前、后3个月、6个月射血分数(LVEF)及左心室腔径变化,并观察患者的血压(BP)、心率(HR)、6min步行试验及死亡率的变化。结果:两组治疗后心功能均有改善,但A组比B组明显。与治疗前相比,两组治疗后3个月与6个月的超声心动图测量指标均有明显改善,心率、血压明显下降。两组治疗后6个月与治疗前相比6min步行试验均有明显提高(P<0.01),而A组较B组更为显著。死亡率无显著性差异(P>0.05)。结论:卡维地洛与对慢性心力衰竭的治疗是有效和安全的。而在运动耐量改善方面,卡维地较洛美托洛尔更为明显。更多还原

【Abstract】 Objective: To study the effect and safety of carvedibol and metoprolol on chronic heart failure(CHF).Method: 88 cases patients with CHF were divided into group A(with carvedilol) 46 cases and group B 42 cases(with Metoprolol).The LVEF and the change of left caliber detected by the colour doppler ECG before treatment 3 month 6 month after treatment on the basis with similarity clinical symptoms observed the change of BP HR.6min walking test and the death rate.Result: The heart function were improved in both group while group A is more obvious them group B.The result of ECG were improved,HR and BP decreased significantly 3 month 6 month after treatment comparetively.The 6min walking test were improved 6 month after treatment in both group(P<0.01).It’s obvious in group A.while there’s no significant difference(P>0.05) in death rate.Conclusion: It’s effective and safety to treat CHF with carvedilol.Carvedilol can better the active tolerance than Metoprolol.更多还原